CONTEXT: Multiple myeloma (MM) is a common hematologic malignancy and is associated with symptom burden and impairments in health-related quality of life (HRQL). OBJECTIVES: To develop a disease-specific, patient-reported outcome (PRO) measure for the assessment of HRQL among patients with MM as part of the Functional Assessment of Cancer Therapy (FACT) measurement system. METHODS: HRQL concerns and symptoms associated with MM were tabulated based on a literature review, and 52 candidate PRO items were identified. Expert clinicians (n=13) rated 52 items on relevance to HRQL for MM patients (0-3 scale). Experts added 11 items for comprehensive PRO assessment in MM. A list of 63 candidate items was rated (0-3 scale) by 13 MM patients enrolled through the International Myeloma Foundation website. Qualitative data and quantitative item ratings were reviewed to select FACT-MM scale items. RESULTS: Expert clinicians provided the highest HRQL relevance ratings for bone pain, bodily pain, difficulty walking (2.9), tiring easily (2.6), feeling discouraged (2.5), interference with activities and difficulty with self-care as a result of bone pain (2.5), and fatigue (2.5). Mean age of patients was 57 years; Eastern Cooperative Oncology Group performance status was 0 (38%), 1 (31%), or 2 (31%). Quantitative ratings by patients identified sexual function (1.3), uncertainty about health (1.2), fatigue (1.0), weight gain (1.0), and emotional concerns, such as worry about new symptoms and difficulty planning for the future (1.0) as most relevant to HRQL. CONCLUSION: The 14-item FACT-MM PRO measure was developed based on expert clinician and patient data, ensuring relevance to HRQL for MM patients.
CONTEXT: Multiple myeloma (MM) is a common hematologic malignancy and is associated with symptom burden and impairments in health-related quality of life (HRQL). OBJECTIVES: To develop a disease-specific, patient-reported outcome (PRO) measure for the assessment of HRQL among patients with MM as part of the Functional Assessment of Cancer Therapy (FACT) measurement system. METHODS: HRQL concerns and symptoms associated with MM were tabulated based on a literature review, and 52 candidate PRO items were identified. Expert clinicians (n=13) rated 52 items on relevance to HRQL for MM patients (0-3 scale). Experts added 11 items for comprehensive PRO assessment in MM. A list of 63 candidate items was rated (0-3 scale) by 13 MM patients enrolled through the International Myeloma Foundation website. Qualitative data and quantitative item ratings were reviewed to select FACT-MM scale items. RESULTS: Expert clinicians provided the highest HRQL relevance ratings for bone pain, bodily pain, difficulty walking (2.9), tiring easily (2.6), feeling discouraged (2.5), interference with activities and difficulty with self-care as a result of bone pain (2.5), and fatigue (2.5). Mean age of patients was 57 years; Eastern Cooperative Oncology Group performance status was 0 (38%), 1 (31%), or 2 (31%). Quantitative ratings by patients identified sexual function (1.3), uncertainty about health (1.2), fatigue (1.0), weight gain (1.0), and emotional concerns, such as worry about new symptoms and difficulty planning for the future (1.0) as most relevant to HRQL. CONCLUSION: The 14-item FACT-MM PRO measure was developed based on expert clinician and patient data, ensuring relevance to HRQL for MM patients.
Authors: Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Philip Cole; Jack S Mandel; Martin M Oken; Dimitrios Trichopoulos Journal: Int J Cancer Date: 2007 Impact factor: 7.396
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Loretta A Williams; Nina D Shah; Sheeba K Thomas; Valen E Johnson; Richard E Champlin; Charles S Cleeland; Tito R Mendoza Journal: J Hematol Oncol Date: 2013-02-05 Impact factor: 17.388
Authors: Thomas R Osborne; Christina Ramsenthaler; Stephen A Schey; Richard J Siegert; Polly M Edmonds; Irene J Higginson Journal: BMC Cancer Date: 2015-04-14 Impact factor: 4.430
Authors: Christina Ramsenthaler; Wei Gao; Richard J Siegert; Steve A Schey; Poly M Edmonds; Irene J Higginson Journal: Qual Life Res Date: 2017-07-27 Impact factor: 4.147
Authors: Deepti Soodgupta; Michelle A Hurchla; Majiong Jiang; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen Journal: PLoS One Date: 2013-02-08 Impact factor: 3.240
Authors: P Sonneveld; S G Verelst; P Lewis; V Gray-Schopfer; A Hutchings; A Nixon; M T Petrucci Journal: Leukemia Date: 2013-06-20 Impact factor: 11.528
Authors: Thomas R Osborne; Christina Ramsenthaler; Susanne de Wolf-Linder; Stephen A Schey; Richard J Siegert; Polly M Edmonds; Irene J Higginson Journal: BMC Cancer Date: 2014-07-09 Impact factor: 4.430
Authors: Don Robinson; Dixie-Lee Esseltine; Antoine Regnault; Juliette Meunier; Kevin Liu; Helgi van de Velde Journal: Br J Haematol Date: 2016-06-05 Impact factor: 6.998
Authors: Joan Blade; Miguel Ángel Calleja; Juan José Lahuerta; José Luis Poveda; Héctor David de Paz; Luis Lizán Journal: BMJ Open Date: 2018-02-22 Impact factor: 2.692